The latest news and insights from Genoa Healthcare.
On January 21, 2025, the FDA announced the approval of Spravato® nasal spray as a monotherapy treatment for treatment-resistant depression (TRD), making this medication the first and only monotherapy option...
Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...
Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...
Genoa Healthcare recently hosted a webinar where Pharmaceutical Program Manager Allie Butler, PharmD, and Clinical Pharmacist Cameron Yenney, PharmD, discussed the latest drug trends in behavioral health. Watch the recording...
Staying on top of new medication therapy options for your consumers living with schizophrenia can be difficult. Learn how the new FDA-approved medication, Cobenfy – approved on September 26, 2024...
By Jennifer Finocchiaro, PharmD, AAHIVE The role of the pharmacist has changed significantly over the years, expanding from medication dispensing and counseling to providing direct patient care. As the pharmacy...
Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...
Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to...
Staying on top of new drug launches and shortages can be difficult. Read Genoa Healthcare’s latest drug trend report for an overview and connect with your local pharmacy team to...
Learn more about this new treatment option for adults living with schizophrenia Genoa is here to help keep you informed on the latest in behavioral health medications. Read on to...